Management of infections caused by extended-spectrum β–lactamase-producing Enterobacteriaceae: current evidence and future prospects

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Anti-Infective Therapy

• Publication date

  2018-02-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14787210.2018.1436966PMID 29402125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty Opinions recommendation of The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

  2018cited by this paper
• Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

  2017cited by this paper
• Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010-2013.

  2017cited by this paper
• Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan.

  2017cited by this paper
• The Use of Noncarbapenem &bgr;-Lactams for the Treatment of Extended-Spectrum &bgr;-Lactamase Infections

  2017cited by this paper
• Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia.

  2017cited by this paper
• Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach

  2017cited by this paper
• Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy

  2017cited by this paper
• Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.

  2017cited by this paper
• Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

  2017cited by this paper
• Changes in minimum inhibitory concentration of levofloxacin for Escherichia coli strains isolated from urine samples in mainland China, 2004 to 2014.

  2017cited by this paper
• Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial

  2017cited by this paper
• Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.

  2016cited by this paper
• Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections

  2016cited by this paper
• A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

  2016cited by this paper
• Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections.

  2016cited by this paper
• Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

  2016cited by this paper
• Tackling Threats and Future Problems of Multidrug-Resistant Bacteria.

  2016cited by this paper
• Commentary: Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs

  2016cited by this paper
• Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems

  2016cited by this paper
• Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia

  2016cited by this paper
• Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria

  2016cited by this paper
• Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.

  2016cited by this paper
• Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

  2016cited by this paper
• New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.

  2016cited by this paper
• Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.

  2016cited by this paper
• Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.

  2016cited by this paper
• Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

  2016influential reference
• Detection of expanded-spectrum β-lactamases in Gram-negative bacteria in the 21st century

  2015cited by this paper
• Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.

  2015cited by this paper
• Extended Spectrum Beta-lactamases: Definition, Classification and Epidemiology.

  2015cited by this paper
• Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates

  2015cited by this paper
• Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

  2015cited by this paper
• Clinical Usefulness of the 2010 Clinical and Laboratory Standards Institute Revised Breakpoints for Cephalosporin Use in the Treatment of Bacteremia Caused by Escherichia coli or Klebsiella spp.

  2015cited by this paper
• Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

  2015influential reference
• Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.

  2015cited by this paper
• β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials.

  2015cited by this paper
• Ceftolozane/Tazobactam: A Novel Cephalosporin/β‐Lactamase Inhibitor Combination

  2015cited by this paper
• Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae

  2015cited by this paper
• Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.

  2015cited by this paper
• Editorial commentary: Bloodstream infection caused by extended-spectrum β-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?

  2015cited by this paper
• Clinical and microbiological characteristics of adult patients with recurrent 1 bacteraemia caused by extended-spectrum β-lactamase-producing 2 Escherichia coli or Klebsiella pneumoniae 3 4

  2015cited by this paper
• Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study.

  2015cited by this paper
• Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients

  2015cited by this paper
• β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?

  2015cited by this paper
• Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

  2015cited by this paper
• Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-Lactamases.

  2014cited by this paper
• Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.

  2014cited by this paper
• Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia

  2014cited by this paper
• Resistance surveillance program report for selected European nations (2011).

  2014cited by this paper
• Escherichia coli bacteraemia: 2 years of prospective regional surveillance (2010-12).

  2014cited by this paper
• Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.

  2014cited by this paper
• OXA β-Lactamases

  2014cited by this paper
• The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.

  2014cited by this paper
• Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

  2013cited by this paper
• Predominance of Klebsiella pneumoniae ST14 carrying CTX-M-15 causing neonatal sepsis in Tanzania

  2013cited by this paper
• Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

  2013cited by this paper
• Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli

  2013cited by this paper
• The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.

  2013cited by this paper
• Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model

  2013cited by this paper
• Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance.

  2013cited by this paper
• Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.

  2013cited by this paper
• Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

  2013cited by this paper
• Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.

  2013cited by this paper
• Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

  2013cited by this paper
• Positive culture for extended-spectrum β-lactamase during acute prostatitis after prostate biopsy is a risk factor for progression to chronic prostatitis.

  2013cited by this paper
• Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

  2012cited by this paper
• Carbapenem Therapy for Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli or Klebsiella pneumoniae: Implications of Ertapenem Susceptibility

  2012cited by this paper
• Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis.

  2012cited by this paper
• Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community.

  2012cited by this paper
• Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

  2012cited by this paper
• Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli

  2012cited by this paper
• β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

  2012cited by this paper
• Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

  2012cited by this paper
• Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.

  2012cited by this paper
• Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant Organisms

  2012cited by this paper
• Clinical Outcomes with Ertapenem as a First-Line Treatment Option of Infections Caused by Extended-Spectrum β-Lactamase Producing Gram-Negative Bacteria

  2012cited by this paper
• Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.

  2012cited by this paper
• Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.

  2012cited by this paper
• Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.

  2012cited by this paper
• The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.

  2012cited by this paper
• Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy

  2011cited by this paper
• Susceptibility of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae According to the New CLSI Breakpoints

  2011cited by this paper
• Extended-spectrum Beta-lactamases: A Brief Clinical Update

  2011cited by this paper
• Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.

  2010cited by this paper
• Three Decades of β-Lactamase Inhibitors

  2010cited by this paper
• Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

  2010cited by this paper
• Worldwide Experience with the Use of Doripenem against Extended-Spectrum-β-Lactamase-Producing and Ciprofloxacin-Resistant Enterobacteriaceae: Analysis of Six Phase 3 Clinical Studies

  2010cited by this paper
• Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms.

  2010cited by this paper
• Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli-Related Complicated Lower Urinary Tract Infection

  2010cited by this paper
• Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.

  2010cited by this paper
• Updated Functional Classification of β-Lactamases

  2009cited by this paper
• Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007

  2009cited by this paper
• Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.

  2009cited by this paper
• A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.

  2009cited by this paper
• Cephalosporin MIC Distribution of Extended-Spectrum-β-Lactamase- and pAmpC-Producing Escherichia coli and Klebsiella Species

  2009cited by this paper
• Sulbactam-containing β-lactamase inhibitor combinations

  2008cited by this paper
• Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.

  2008cited by this paper
• The spread of CTX-M-type extended-spectrum beta-lactamases.

  2008cited by this paper
• Efficacy of Ertapenem for Consolidation Therapy of Extended-Spectrum β-lactamase-Producing Gram-Negative Infections: A Case Series Report

  2008cited by this paper

• Analysis of clinical characteristics of patients with coronavirus disease 2019 based on a superior carbapenem-resistant Enterobacterales identification strategy

  2025cites this paper
• Advancements in human health risk, detection and bioremediation of bacterial contaminants in water: A review

  2025cites this paper
• Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae in Dogs from Cape Verde and São Tomé and Príncipe: Implications for Public Health

  2025cites this paper
• Bactericidal Properties, Biofilm Formation Inhibition, and Chemical Profiling of Piper argyrites and Piper betel L.

  2025cites this paper
• Evaluation of adhesin genes and risk factors associated with urinary tract infections by drug-resistant uropathogenic Escherichia coli in North of Iran.

  2024cites this paper
• Comparison of ERIC carbapenem-resistant Enterobacteriaceae test, BD Phoenix CPO detect panel, and NG-test CARBA 5 for the detection of main carbapenemase types of carbapenem-resistant Enterobacterales.

  2024cites this paper
• Probiotic cell-free supernatant as effective antimicrobials against Klebsiella pneumoniae and reduce antibiotic resistance development

  2024cites this paper
• How to tailor recommendations on the treatment of multi-drug resistant Gram-negative infections at country level integrating antibiotic stewardship principles within the GRADE-ADOLOPMENT framework.

  2023cites this paper
• Increased Incidence and Risk Factors of Infections by Extended-Spectrum β-Lactamase-Producing Enterobacterales During the COVID-19 Pandemic: A Retrospective Case-Control Study

  2023cites this paper
• Risk Factors for Community Colonization With Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study

  2023cites this paper
• Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?

  2023cites this paper
• Global evaluation of the antibacterial activity of Ceftolozane/Tazobactam against ESBLs-producing Escherichia coli and Klebsiella pneumoniae: a systematic review and meta-analysis

  2023cites this paper
• Carbapenem resistant Enterobacterales in the United Arab Emirates: a retrospective analysis from 2010 to 2021

  2023cites this paper
• Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives

  2022cites this paper
• Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) and Carbapenem-Resistant Enterobacterales (CRE) in Healthcare and Community Settings in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study.

  2022cites this paper
• Diagnosis and Treatment-Spectrum Beta-Lactamase and Multidrug Resistance Bacterial

  2022cites this paper
• Panorama of Bacterial Infections Caused by Epidemic Resistant Strains

  2022cites this paper
• Phage-antibiotic synergy: Cell filamentation is a key driver of successful phage predation

  2022cites this paper
• An Overview on Phenotypic and Genotypic Characterisation of Carbapenem-Resistant Enterobacterales

  2022cites this paper
• Сепсис, септический шок. Возбудитель инфекции: есть ли разница в подходах? Как быть с карбапенем-резистентными возбудителями?

  2022cites this paper
• Frequency of High Antimicrobial Susceptibility Carbapenemase Producing Enterobacteriaceae in Clinical Isolates of a Set of Population

  2022cites this paper
• Synergistic Antibacterial Effects of Meropenem in Combination with Aminoglycosides against Carbapenem-Resistant Escherichia coli Harboring blaNDM-1 and blaNDM-5

  2021cites this paper
• Stewardship program on carbapenem prescriptions in a tertiary hospital for adults and children in France: a cohort study

  2021cites this paper
• Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae

  2021cites this paper
• OXA-48 Carbapenemase-Producing Enterobacterales in Spanish Hospitals: An Updated Comprehensive Review on a Rising Antimicrobial Resistance

  2021cites this paper
• Drug-related problems among patients with infectious disease admitted to medical wards of Wollega University Referral Hospital: Prospective observational study

  2021cites this paper
• Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Causing Community-Acquired Urinary Tract Infections in Children in Colombia

  2021cites this paper
• Antimicrobial Resistance and Molecular Epidemiology of Uropathogenic Escherichia coli Isolated From Female Patients in Shanghai, China

  2021cites this paper
• Prevalence and molecular characterization of multidrug‐resistant Escherichia coli O157 : H7 from dairy milk in the Peshawar region of Pakistan

  2021cites this paper
• Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia

  2021cites this paper
• Calculation of the Zone of Inhibition and Sensitivity Pattern of Fenugreek Seeds Extract and Negila sativa Seeds Extract on ESBL E. coli Growth Plates

  2021influential citation
• Treatment in Infections by Enterobacterales Producing Extended Spectrum Betalactamase. Systematic Review

  2021cites this paper
• In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015-2018.

  2020cites this paper
• Multidrug-Resistant Organisms: Posttransplant Management for Extended-Spectrum Beta-Lactamase Producers and Carbapenem-Resistant Enterobacterales

  2020cites this paper
• Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study.

  2020cites this paper
• Optimization of the antibiotic policy in the Netherlands: SWAB guidelines for antimicrobial therapy of urinary tract infections in adults SWAB Urinary Tract Infections Guidelines Committee

  2020cites this paper
• Antimicrobial Activity of Colistin Against Contemporary (2015 – 2017) P. aeruginosa and A. baumannii Isolates From a Chinese Surveillance Program

  2020cites this paper
• Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections

  2020cites this paper
• Management of Infections Caused by WHO Critical Priority Gram-Negative Pathogens in Arab Countries of the Middle East: A Consensus Paper.

  2020cites this paper
• Panorama de resistencia antimicrobiana de los aislamientos urinarios de pacientes adultos en los servicios de urgencias de Manizales, Caldas, durante el 2018

  2020cites this paper
• In vitro Activity of a New Fourth-Generation Cephalosporin, Cefoselis, Against Clinically Important Bacterial Pathogens in China

  2020cites this paper
• Antagonistic Activities of Cell-Free Supernatants of Lactobacilli Against Extended-Spectrum β-Lactamase Producing Klebsiella pneumoniae and Pseudomonas aeruginosa

  2020cites this paper
• Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

  2019influential citation
• Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study.

  2019cites this paper
• Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections

  2019cites this paper
• Huge Diversity of TEM and SHV β-Lactamases Types Among CTX-M-15-Producing Enterobacteriaceae Species in Tunisia

  2019cites this paper
• The Influence of Dimerization on the Pharmacokinetics and Activity of an Antibacterial Enzyme Lysostaphin

  2019cites this paper
• Antimycobacterial strategies to evade antimicrobial resistance in the nontuberculous mycobacteria

  2019cites this paper
• Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects

  2018cites this paper
• Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?

  2018cites this paper
• Travel to Asia is a strong predictor for carriage of cephalosporin resistant E. coli and Klebsiella spp. but does not explain everything; prevalence study at a Norwegian hospital 2014–2016

  2018cites this paper
• The uncertainties of the diagnosis and treatment of a suspected urinary tract infection in elderly hospitalized patients

  2018cites this paper